Press Releases Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
2.24 ^USD	+0.45%		-27.74%	-30.02%

30/04	Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	CI
26/03	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur	01/05	AQ
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™	30/04	BU
Virpax Pharmaceuticals Reports 2023 Year-End Results	26/03	BU
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price	28/02	AQ
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price	27/02	BU
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.	27/02	BU
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research	07/02	BU
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting	29/12	BU
Virpax Pharmaceuticals : Failure to Satisfy Listing Rule - Form 8-K	13/12	PU
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing	20/11	AQ
Virpax Pharmaceuticals Announces Leadership Transition	20/11	AQ
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing	17/11	BU
Virpax Pharmaceuticals Announces Leadership Transition	17/11	BU
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments	16/11	BU
Virpax Pharmaceuticals Announces that Envelta Remains on Track for Trial in Humans Following FDA Review	01/11	AQ
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review	31/23/31	BU
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research	12/23/12	BU
Virpax Pharmaceuticals, Inc. - Gerald W. Bruce Appointed President and CEO of Novvae Pharmaceuticals	03/23/03	AQ
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals	02/23/02	BU
Virpax Pharmaceuticals Announces Results of Probudur Dose Escalation Studies	28/23/28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Press Releases

Filters